Edmonton, Canada

John Lewis

This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Entos Pharmaceuticals Inc., Lawson Health Research Institute, London Health Sciences Centre Research Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Lewis. Retrieved from https://idiyas.com/inventor/john-lewis-ora6kydg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 71.4

 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Edmonton, CA (2017 - 2022)
  • London, CA (2019 - 2022)

Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: John Lewis: Innovator in Membrane Fusion and Cancer Treatment

Introduction

John Lewis is a notable inventor based in Edmonton, Canada. He has made significant contributions to the fields of biotechnology and medicine, holding a total of 7 patents. His work primarily focuses on recombinant polypeptides and methods for diagnosing and treating metastatic cancer.

Latest Patents

One of his latest patents involves recombinant polypeptides for membrane fusion. This invention discloses a recombinant polypeptide designed to facilitate membrane fusion, featuring a sequence with at least 80% identity to the ectodomain of the p14 fusion-associated small transmembrane (FAST) protein. The polypeptide includes a functional myristoylation motif, a transmembrane domain from a FAST protein, and a sequence with at least 80% identity to the endodomain of the p15 FAST protein. Additionally, a targeting ligand can be incorporated into the recombinant polypeptide for selective fusion. This polypeptide can be utilized in liposome membranes to deliver bioactive compounds, such as siRNA, or can be mixed with a lipid carrier to induce cell-cell fusion and heterokaryon formation.

Another significant patent pertains to methods for diagnosing and treating metastatic cancer. This invention outlines methods that involve detecting or modulating the expression of various genes in a biological sample from a subject. The genes include Kif3b, ACTB, SRPK1, and several others, which play a role in cancer progression.

Career Highlights

Throughout his career, John Lewis has worked with prominent organizations such as Entos Pharmaceuticals Inc. and Lawson Health Research Institute. His innovative work has contributed to advancements in therapeutic strategies and diagnostic methods in oncology.

Collaborations

John has collaborated with notable colleagues, including Roy Duncan and Eileen Kathryn Clancy. Their combined expertise has furthered the impact of his research and inventions.

Conclusion

John Lewis is a distinguished inventor whose work in recombinant polypeptides and cancer treatment methods has made a significant impact in the field of biotechnology. His contributions continue to influence research and development in medical applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…